Concordant with FGFR2 signaling inhibition, pemigatinib inhibits cell viability in vitro with a 50% inhibitory concentration (IC50) of 4 nM in the PDC (Fig. 4A), whereas the IC50 of pemigatinib is >400 nM in SSP25 cells, an established ICC cell line with no FGFR alterations (Supplementary Fig. 2A). The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.